Which insulins are classified as rapid-acting?

Rapid-acting insulins are specifically designed to mimic the natural insulin response that occurs after eating. They have a quick onset of action, typically within 15 minutes after injection, peak in about 1 to 2 hours, and their effects can last for a few hours. This rapid response is essential for managing postprandial (after meal) blood glucose levels.

Novolog (insulin aspart), Humalog (insulin lispro), and Apidra (insulin glulisine) are the three main types of rapid-acting insulins commonly used in diabetes management. They are often utilized in conjunction with longer-acting insulins to provide both immediate and sustained glycemic control, allowing patients the flexibility to manage their blood sugar levels around meals effectively.

In comparison, other insulins mentioned, such as Levemir and Lantus, are long-acting insulins that provide a steady level of insulin over an extended period, and Regular and NPH insulins are classified as intermediate-acting. Therefore, recognizing the distinct characteristics of insulin types is critical for effective diabetes management.